Clinical Trials Logo

Salivary Gland Tumors clinical trials

View clinical trials related to Salivary Gland Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT05601401 Recruiting - Clinical trials for Salivary Gland Tumors

Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2

Start date: March 31, 2022
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the efficacy and safety of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic salivary cancer.

NCT ID: NCT05000892 Recruiting - Clinical trials for Salivary Gland Tumors

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Start date: December 10, 2021
Phase: Phase 2
Study type: Interventional

This proposed study will evaluate the efficacy and safety of preoperative administration Sintilimab combined with nab-paclitaxel and carboplatin in salivary gland malignant neoplasms who are about to undergo surgery. Monoclonal antibodies, such as Sintilimab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will be helpful for comprehensive exploratory characterization of tumor immune microenvironment and circulating immune cells in these patients.

NCT ID: NCT04825938 Not yet recruiting - Clinical trials for Salivary Gland Tumors

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Start date: April 30, 2021
Phase: Phase 2
Study type: Interventional

This proposed study will evaluate the efficacy and safety of preoperative administration Toripalimab combined with nab-paclitaxel and carboplatin in salivary gland malignant neoplasms who are about to undergo surgery.Monoclonal antibodies, such as Toripalimab , may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.This trial will be helpful for comprehensive exploratory characterization of tumor immune microenvironment and circulating immune cells in these patients.

NCT ID: NCT02921984 Completed - Clinical trials for Head and Neck Cancer

Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors

Start date: September 2013
Phase: Phase 1
Study type: Interventional

The role of postoperative concurrent chemotherapy (CCT) has not been established for salivary gland tumors (SGTs). This prospective study was conducted to evaluate the feasibility and safety of customized CCT regimens based on the gene targets of SGTs.

NCT ID: NCT02776163 Recruiting - Clinical trials for Head and Neck Cancer

Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors

Start date: June 1, 2016
Phase: Phase 2
Study type: Interventional

This is a non-randomized, phase II, open label study of postoperative current chemoradiotherapy for high-risk malignant salivary gland tumors of head and neck.The primary purpose of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy in these patients.